1. Recent Evidence on the Use of Tiotropium Bromide in Pediatric Asthma: Summary Results of Eight Clinical Trials
- Author
-
Ricardo Cardona-Villa and Manuela Tejada-Giraldo
- Subjects
Drug ,Pediatrics ,medicine.medical_specialty ,Allergy ,business.industry ,media_common.quotation_subject ,Medicine (miscellaneous) ,Muscarinic antagonist ,Disease ,Tiotropium bromide ,medicine.disease ,respiratory tract diseases ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,business ,human activities ,Lung function ,media_common ,Asthma ,medicine.drug - Abstract
To collect the existing information on tiotropium as an add-on treatment for asthma in children and adolescents. The use of tiotropium bromide in children between 1 and 6 years old. Asthma is a disease that can be difficult to control. For the treatment of this, there is a combination of medications, but often complete control of the disease is not achieved. The addition of tiotropium, a long-acting muscarinic antagonist, to treatment with inhaled corticosteroids has been recommended to improve lung function in adults and adolescents who have uncontrolled asthma. Here we present a review of the eight clinical trials that show the use of tiotropium in pediatric patients with asthma. The results demonstrate efficacy in improving lung function (evaluated with different parameters), in both children and adolescents; it also shows the safety of the drug in short and long-term uses.
- Published
- 2018